Diabetes Mellitus, Type 2 Clinical Trial
Official title:
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0472-0147 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
Verified date | September 2022 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is investigating the safety and tolerability of the new medicine NNC0472-0147, its concentrations in the blood and its effect on blood sugar for the treatment of diabetes. Another goal of the study is to determine an effect of NNC0472-0147 on cholesterol. The first part of the study is conducted in healthy people, while the second part involves people with type 2 diabetes (T2DM). The study will test how NNC0472-0147 is tolerated by the body, how it is taken up in the blood, how long it stays there and how much blood sugar is lowered. In part 1, participants will either get the new medicine NNC0472-0147 or placebo (an injection that does not contain active medicine) - which treatment is decided by chance. In part 2, participants will either get the new medicine NNC0472-0147 or insulin glargine - which treatment is decided by chance. It is the first time that NNC0472-0147 is tested in humans. Participants will get once daily injections of either NNC0472-0147 or insulin glargine for a treatment period of fourteen days. The injections will be given under the skin (subcutaneously, s.c.) of the left thigh. Participants will be in the study for about 7 weeks. There will be 15 visits with the study doctor. People cannot be in the study if the study doctor thinks that there are risks for their health. Only women who cannot become pregnant are allowed to participate.
Status | Completed |
Enrollment | 36 |
Est. completion date | September 25, 2020 |
Est. primary completion date | September 25, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: Part 1: - Male - Aged 18-55 years (both inclusive) at the time of signing nformed consent. Part 2: - Male, or female of non-child bearing potential. Non-child bearing potential is defined by being surgically sterilised (documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (no menses for 12 months without an alternative medical cause) prior to the day of screening. - Aged 18-64 years (both inclusive) at the time of signing informed consent. - Diagnosed with T2DM at least 180 days prior to the day of screening. - Treated with any insulin for 90 days or longer prior to the day of screening. - Low-density lipoprotein cholesterol level above 1.80 mmol L. Exclusion Criteria: Part 1: - Male of reproductive age who or whose partner(s) is not using highly effective contraceptive methods (highly effective contraceptive measures as required by local regulation or practice). Highly effective contraceptive measures include that the male subject uses a condom during intercourse and that the partner practices highly effective contraception (risk of pregnancy must be lower than 1%). In addition, subjects must not donate sperm for the duration of the trial. Part 2: - Male of reproductive age who or whose partner(s) is not using highly effective contraceptive methods (highly effective contraceptive measures as required by local regulation or practice). Highly effective contraceptive measures include that the male subject uses a condom during intercourse and that the partner practices highly effective contraception (risk of pregnancy must be lower than 1%). In addition, subjects must not donate sperm for the duration of the trial. - Use of oral antidiabetic drugs (OADs) other than metformin or use of glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. exenatide, liraglutide, semaglutide) within 90 days prior to the day of screening. - Treatment with peptide proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors within 180 days prior to the day of screening. |
Country | Name | City | State |
---|---|---|---|
Germany | Novo Nordisk Investigational Site | Mainz | |
Germany | Novo Nordisk Investigational Site | Neuss |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1: Number of treatment emergent adverse events | Number of events | From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 15, visit 6) | |
Primary | Part 2: Number of treatment emergent adverse events | Number of events | From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 30, visit 14) | |
Secondary | Number of hypoglycaemic episodes of alert value (level 1) below 3.9 mmol/L (70 mg/dL) and equal to or above 3.0 mmol/L (54 mg/dL) | Number of episodes | From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 15, visit 6) | |
Secondary | Number of hypoglycaemic episodes of alert value (level 1) below 3.9 mmol/L (70 mg/dL) and equal to or above 3.0 mmol/L (54 mg/dL) | Number of episodes | From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 30, visit 14) | |
Secondary | Number of clinically significant hypoglycaemic episodes (level 2) below 3.0 mmol/L (54 mg/dL) | Number of episodes | From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 15, visit 6) | |
Secondary | Number of clinically significant hypoglycaemic episodes (level 2) below 3.0 mmol/L (54 mg/dL) | Number of episodes | From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 30, visit 14) | |
Secondary | Number of severe hypoglycaemic episodes (level 3) | Number of episodes | From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 15, visit 6) | |
Secondary | Number of severe hypoglycaemic episodes (level 3) | Number of episodes | From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 30, visit 14) | |
Secondary | Area under the serum NNC0472-0147 concentration-time curve after a single dose | pmol*h/L | From 0 hours until infinity after a single IMP administration at day 1 (visit 2). | |
Secondary | Maximum observed serum NNC0472-0147 concentration after a single dose | pmol/L | From 0 hours until last measurement time after a single IMP administration at day 1 (visit 2) | |
Secondary | Area under the serum NNC0472-0147 concentration-time curve during one dosing interval at steady state | pmol*h/L | From 0 to 24 hours after last multiple IMP administration at day 14 (visit 9) | |
Secondary | Maximum observed serum NNC0472-0147 concentration at steady state | pmol/L | From 0 to 24 hours after last multiple IMP administration at day 14 (visit 9) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |